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High frequency of resistance to the drugs isoniazid and rifampicin 
among tuberculosis cases in the City of Cabo de Santo Agostinho, 
an urban area in Northeastern Brazil
Alta freqüência de resistência às drogas isoniazida e rifampicina 
em tuberculose na Cidade do Cabo de Santo Agostinho, 
uma área urbana do nordeste do Brasil
Marcilio Baliza1, 7, Artur Henrique Bach1, Gabriel Lobo de Queiroz1, Inês Cardoso Melo2,
Maria Madileuza Carneiro3, Maria de Fátima Pessoa Militão de Albuquerque1, Philip Suffys4,
Laura Rodrigues5, Ricardo Ximenes6 and Norma Lucena-Silva1, 8
ABSTRACT
The objective of the present study was to investigate the frequency and risk factors for developing multidrug-resistant tuberculosis in Cabo de Santo 
Agostinho, PE. This was a prospective study conducted from 2000 to 2003, in which suspected cases were investigated using bacilloscopy and culturing. 
Out of 232 confirmed cases of tuberculosis, culturing and antibiotic susceptibility tests were performed on 174. Thirty-five of the 174 cultures showed 
resistance to all drugs. The frequencies of primary and acquired resistance to any drug were 14% and 50% respectively, while the frequencies of 
primary and acquired multidrug resistance were 8.3% and 40%. Previous tuberculosis treatment and abandonment of treatment were risk factors for 
drug resistance. The high levels of primary and acquired resistance to the combination of isoniazid and rifampicin contributed towards the difficulties 
in controlling tuberculosis transmission in the city. 
Key-words: Tuberculosis. Drug resistance. Multidrug resistance. Risk factors.   
RESUMO
O objetivo do presente estudo foi investigar a freqüência e fatores de risco para o desenvolvimento de tuberculose multidroga resistente, na Cidade 
do Cabo de Santo Agostinho, PE. Este é um estudo prospectivo realizado entre 2000-2003 onde casos suspeitos foram investigados por baciloscopia 
e cultura. De 232 casos de tuberculose confirmados, 174 tiveram cultura e antibiograma realizados. Trinta e cinco das 174 culturas mostraram 
resistência a qualquer uma das drogas. A freqüência de resistência primária e adquirida a qualquer droga foi 14% e 50% respectivamente enquanto 
a freqüência primária e adquirida para multidroga resistência foi 8,3% e 40%. Tratamento prévio para tuberculose ou abandono de tratamento 
consistiu em fatores de risco para resistência a drogas. Os altos níveis de resistência primária e adquirida a combinação isoniazida e rifampicina 
contribuem para as dificuldades no controle da transmissão da tuberculose no Cabo.
Palavras-chaves: Tuberculose. Resistência a drogas. Multidroga resistência. Fatores de risco.
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The increasing frequency of drug-resistant tuberculosis (TB), 
which has been leading to failure to respond to either isoniazid 
(INH) or rifampicin (RMP) is of great concern in relation to 
successful implementation of large-scale regional TB control 
programs. In Brazil, the first-line drugs for TB treatment in use 
since 1982 are INH and RMP for six months in association with 
pyrazinamide (PZA) for the first two months. The drugs are 
supplied by the government, without cost to the patient, and the 
treatment is based on self-administration.
The World Health Organization (WHO) defines multidrug-
resistant tuberculosis (MDR-TB) as TB involving resistance 
to at least INH and RMP. However, the Brazilian Consensus 
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for Tuberculosis that was agreed in 1997 classifies MDR-TB as 
tuberculosis caused by Mycobacterium that is resistant to more 
than two drugs including INH and RMP11. Primary resistance 
refers to the presence of resistant isolates of Mycobacterium in 
patients who, in response to direct questioning, deny having had 
any prior anti-TB treatment; it is thus a consequence of transmission 
of resistant isolates. Acquired resistance is defined as the presence of 
resistant isolates of Mycobacterium in patient who, in response to direct 
questioning, admit having been treated for tuberculosis; it is thus due to 
selection of the bacterial population by development of mutation(s) that 
confer(s) survival advantages under antibiotic selective pressure15. The 
recommended treatment for multidrug-resistant tuberculosis is more 
toxic, takes at least three times longer and is a hundred times more 
expensive than a short course of treatment. It is also less successful16.
In 2004, WHO published a survey of frequencies of drug-
resistant tuberculosis simultaneously in 74 countries around the 
world. Among new TB cases, the median prevalences of overall 
resistance, monoresistance and multiresistance were 10.2%, 7% 
and 1.1% respectively. The prevalence of any monoresistance to 
streptomycin (SM) was 6.3%, to INH 5.6%, to RPM 1.4% and 
to ethambutol (EMB) 0.8%. Analysis among previously treated 
cases was possible for 65 different settings, and it was found 
that the median prevalence of any resistance was 18.4%, with 
eleven settings reporting resistance over 50%, while the median 
prevalence of multidrug resistance was 7%24. The prevalence of 
any monoresistance was 11.4% for SM, 14.4% for INH, 8.7% for 
RMP and 3.5% for EMB. The WHO study reported resistance data 
for 39 more settings than in the previous worldwide survey, but 
in spite of the great variation in the prevalence of TB resistance, 
it was possible to identify new hotspots with high prevalence of 
multidrug resistance among new cases. 
Previous treatment for tuberculosis is the predominant 
determinant for the development of MDR-TB5 20. Other risk factors 
are poor adherence to treatment, the presence of cavitary lesions 
on chest X-ray and HIV infection6 18 22.
In Brazil, culturing and drug susceptibility testing for 
Mycobacterium tuberculosis strains is not performed on a 
routine basis and, except for a few studies, the information 
available on drug resistance is scarce. Information from the 
worldwide survey coordinated by WHO produced the estimate 
that, in this country, the national prevalence of acquired resistance 
to any drug was less than 20% and multidrug resistance was less 
than 10%. Primary resistance to any drug was less then 10% and 
primary multidrug resistance was less then 1%24. However, Brazil 
is a very large country with considerable regional differences 
regarding cultural and socioeconomic conditions. Demographic 
factors vary also within each region; therefore, heterogeneity is 
expected in these rates. This has been demonstrated by recent 
studies such as one performed in São Paulo, Brazil’s largest city, 
with an overall resistance of 15.5%. Among previously treated 
cases, the prevalence of resistance was 27% and multidrug 
resistance was 16.7%. Among new cases, the prevalence of any 
resistance was 11% and multidrug resistance was only 1%21.
Cabo de Santo Agostinho, the area of the present study, is an 
industrial city in northeastern Brazil with an annual incidence 
of TB of about 60 per 100,000 inhabitants, a 20% treatment 
abandonment rate and no information on the frequency of drug 
resistance until the present study was conducted. The prospective 
cohort presented here was designed to characterize the drug 
resistance profile of Mycobacterium strains isolated from patients 
who were attended for TB investigation at public outpatient clinics 
and to investigate the risk factors for the development of MDR-TB
in the city of Cabo de Santo Agostinho.
MATERIAL AND METHODS
Study design and population. A cohort study was designed 
to analyze newly diagnosed TB cases among 773 patients with 
TB-like respiratory symptoms who attended public outpatient 
facilities in Cabo de Santo Agostinho between February 2000 and 
December 2003. At the beginning of this study, the diagnosing of 
TB in Cabo was centralized. Thus, all suspect TB patients were 
referred to the Herbert de Souza Health Center, where they were 
seen by an experienced physician and were invited to have an 
appointment with the research team. Patients who were seen by 
the research team and who agreed to participate in this study 
signed an informed consent statement prior to answering a clinical 
and epidemiological questionnaire. Sputa were also collected 
and sent to the Central Laboratory of Pernambuco, which is the 
reference laboratory of the State of Pernambuco for tuberculosis 
diagnosis, for bacilloscopy, culturing and resistance testing. 
Blood samples were sent to the Public Laboratory of Olinda for 
HIV infection testing. 
TB cases were defined by the physician who attended the 
patient, based on the clinic findings, X-ray and bacilloscopy. 
Because not all suspected TB cases were examined by the research 
team, the study population represented a fraction of the TB 
cases notified during the study period. Unfortunately, it was not 
possible to make a comparison between notified TB cases that 
were included in the research database and the overall number 
of TB cases, because the variables used in the official notification 
form were different from those in the questionnaire for the present 
study, other than age and gender, which were similar. Therefore, 
the results presented here might be not representative of the whole 
population of TB cases diagnosed in the City of Cabo de Santo 
Agostinho during the study period.
The Ethics Committee of the Aggeu Magalhães Research Center 
of the Oswaldo Cruz Foundation approved this study.
Microbiological analysis. Acid-fast bacilli were detected 
by means of Ziehl-Neelsen staining. The sputa were then 
decontaminated in accordance with the Petroff method and 
aliquots of 0.1ml were placed in Löwenstein-Jensen medium 
with or without the following antibiotics (Sigma, USA): isoniazid 
(0.2Pg/ml), streptomycin (4Pg/ml), pyrazinamide (2Pg/ml), 
ethambutol (2Pg/ml), ethionamide (2Pg/ml), rifampicin 
(40Pg/ml) or p-nitrobenzoic acid (500Pg/ml). The resistance 
was determined by the proportion method11. In order to increase 
the bacillary load, all smear-negative or weak positive samples 
(+) were first grown in the medium without antibiotics for two 
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weeks and were then subjected to resistance testing. Fast-growing 
Mycobacterium was routinely sent to the “Professor Hélio Fraga” 
National TB Reference Laboratory (Ministry of Health), in Rio de 
Janeiro, for species identification when these cases were detected 
by Regional Laboratories within the Public Laboratory network. 
When a resistant strain was identified on diagnosis, additional 
sputum was collected two or three months after the treatment 
began, for follow-up culturing and resistance testing, which have 
here been termed control cultures. 
Data analysis. A database was constructed containing the 
clinical, epidemiological and laboratory information obtained 
from all patients under investigation for TB at the “Hebert de 
Souza” Public Health Center, using the Epi Info 6.04 software. 
In order to estimate the number of notified TB cases included in 
the cohort, we also analyzed official records of tuberculosis cases 
notified from 2000 to 2003, which were provided by the Health 
Department of Cabo de Santo Agostinho. Both databases were first 
reviewed to exclude any inconsistent data. Instances of identical 
data entries within a 30-day period were taken to be duplicates. 
Cases already undergoing treatment at the beginning of the study 
period were excluded. 
For the resistance analysis, the frequencies of both 
monoresistance and multiresistance were determined. To allow 
comparison with international data, multidrug resistant strains 
were considered to be those that were resistant to at least INH and 
RMP, as defined by WHO. To determine the resistance index, files 
from positive culture on diagnosis were first selected and then 
any files relating to atypical strains that are normally resistant to 
multiple drugs and thus not a subject of our study were excluded. 
Nevertheless, the analysis included other files from patients who 
developed resistance during the course of their treatment, in the 
understanding that this represented infection by a new strain based 
on its resistance profile (Figure 1). The resistance was classified 
as either primary or acquired and, for primary resistance, it 
was calculated by dividing the number of patients with resistant 
strains among new cases by the total number of new cases with 
culturing and resistance testing. For acquired resistance, it was 
calculated by dividing the number of patients with resistant 
strains among previously treated cases by the total number of 
previously treated cases with culturing and resistance testing. 
The risk ratios for the development of drug-resistant TB were 
calculated for biological, clinical and socio-economical factors, 
including history of previous TB and abandonment of treatment, 
using logistic regression. The significance of these associations 
was determined using the chi-squared test and p-values, and Yates 
correction when indicated.
RESULTS
Cohort characterization. In the present study, 773 
symptomatic respiratory cases were investigated for TB 
(Figure 1). The TB diagnosis was confirmed for 232 cases 
interviewed, which represented 50.5% of the 459 notified cases 
during the study period. The official incidence of TB was around 60 
new cases per 100,000 inhabitants per year in the city of Cabo de 
Figure 1 - Selection of the study population. Out of the 268 tuberculosis 
cases screened, 232 were notified by the Health Department of Cabo de 
Santo Agostinho during the study period.
Santo Agostinho. Although some fluctuation in the yearly incidence 
rates could be noticed, no clear upward or downward trend could 
be observed. A different scenario was apparent when observing 
two epidemiological characteristics that are associated with drug 
resistance: abandonment of treatment and disease recurrence 
(Table 1). A considerably higher number of such events were 
observed during the first two years of the study, in comparison 
with the next two years. The mean frequency of abandonment of 
treatment in 2000-2001 was 15.5%, whereas it decreased to 5% in 
2002-2003 (p = 0.004). The mean frequencies of TB recurrence 
were respectively 5.5% and 2.5% for these consecutive two-year 
periods, but this difference was not significant (p = 0.346). It is 
important to point out that two interventions were implemented 
by the city’s Health Department over the study period: community-
based surveillance in 2002 and decentralization of the healthcare 
system in 2003. These may have had an influence on the fall in 
the abandonment rate.
Tuberculosis was more frequent among men than among 
women (2:1), and the majority of the cases (86.6%) occurred 
within the economically active age group (20 to 64 years). Alcohol 
consumption and smoking were reported by 65.7% and 59.7% 
of the cases respectively. Histories of previous TB contact and 
anti-TB vaccination were present in 32.5% and 59.7% of cases 
Table 1 - Coefficients of tuberculosis in Cabo de Santo Agostinho, 
2000-2003.
2000 2001 2002 2003 Total
Coefficients (per 100,000)
incidence 61.4 58.8 52.3 67.3
prevalence 81.7 76.5 61.4 80.4
Total - notified cases 125 117 94 123 459
new cases 94 90 80 103 367
retreatment
abandonment 19 19 3 8 45
recurrence 8 6 3 3 20
transferred   8 9 17
not classified 4 2   6
Total - studied cases 60 70 42 60 232
773 symptomatic respiratory cases
268 tuberculosis cases
505 patients without tuberculosis
174 positive cultures with resistance testing
30 resistant strains
at diagnosis
1 child under 16 years
Fast- growing Mycobacterium
kansassi (2) and abscessus (2)
5 new resistant strains
isolated during treatment follow-up
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respectively. During the analysis, information bias was identified 
when assessing socioeconomic factors using the variables of 
employment and income, as measured by the minimum official 
salary in Brazil. There were records of employment activities with 
no regular incomes, thereby leading to imprecise quantification. 
About 70% of the patients were literate.
Culturing results and bacteriological characterization 
of mycobacterial isolates. Among all of the 773 suspected 
cases, Mycobacterium was isolated by means of Löwenstein-Jensen 
culturing in 181 (23.4%) samples, while 559 (72.3%) were negative 
cultures, 10 (1.3%) presented technical problems during the isolation 
procedure and 23 (3%) were not subjected to culturing. Among the 
181 positive cultures, 137 (75.7%) were positive to alcohol-acid 
staining while 44 (24.3%) were smear-negative. All the negative 
cultures were also smear-negative. The bacilloscopy performed by the 
State Laboratory had sensitivity of 75.7%, specificity of 100%, positive 
predictive value of 100% and negative predictive value of 92.7%.  
Thirty out of the 169 isolate samples on which resistance 
testing was performed at diagnosis showed resistance to at least one 
drug. However a further five isolates were obtained from patients 
undergoing treatment and were included in the resistance analysis 
because they were judged to represent new strains (their resistance 
testing showed profiles that differed from what was seen at the 
diagnosis). However, it was not possible to distinguish whether this 
was due to new infection or to selection of a mutant strain during 
the course of the treatment. All 35 Mycobacterium tuberculosis 
isolates were resistant to at least isoniazid. Resistance to at least 
rifampicin was found in 24 (14%) of the isolates. Monoresistance to 
isoniazid occurred in seven (4%) of the isolates. No monoresistance 
to rifampicin was found, and an association between isoniazid and 
rifampicin occurred in 16 (9%) of the cases. Resistance to isoniazid 
and rifampicin, or multidrug resistance, occurred in 24 (14%) of the 
cases. The frequency of primary resistance was 14% and of acquired 
resistance was 50%. The frequency of MDR-TB among new cases was 
8% and among previously treated cases was 40%. The proportions of 
resistance among previously treated cases and new cases were 3.6 for 
monoresistance, 2.6 for two-drug resistance and 8.0 for resistance 
to three or more drugs (Table 2). Secondary and primary resistance 
to the specific combination of isoniazid and rifampicin was 20% and 
6.3% with a ratio of 3.2. In a recent visit to the Cabo Health Center, 
we investigated the outcomes from the patients with drug-resistant TB 
reported here and found that cases of monoresistance to isoniazid 
either presented recurrence or were cured using scheme 1. We also 
observed that most multidrug-resistant cases completed the six-month 
treatment of scheme 1, even though the culture results were provided 
by the research team (data not shown).
Risk factors for developing drug-resistant tuberculosis. 
Comparison of the biological, clinical and epidemiological 
characteristics of the patient groups with drug-sensitive and 
resistant isolates showed that there were no statistically significant 
differences between the groups regarding frequencies of age, 
gender, literacy, being employed/unemployed, income category 
or presence of clinical symptoms. However, previous TB treatment 
and/or presenting a history of abandoning treatment were strongly 
associated with resistance (Table 3). The risk of developing MDR-
TB was higher for those who reported previous TB treatment 
Table 2- Frequency of drug-resistant Mycobacterium tuberculosis among 
cases diagnosed in Cabo de Santo Agostinho, 2000-2003. 
Number Frequency Prevalence Prevalence  Ratio of
(%) of primary of acquired  acquired 
  resistance resistance to primary
    resistance
Mycobacterium 174  13.9 50.0 3.6
tuberculosis isolates     
Any resistance 35 20     -
isoniazid (H) 35 20 - - -
streptomycin (S) 7 4 - - -
rifampicin (R) 24 14 - - -
ethambutol (E) 5 3 - - -
ethionamide (Et) 4 2 - - -
pyrazinamide (Z) 1 1 - - -
H, R (MDR) 24 14 8.3 40.0 4.8
H, S 6 3 - - -
Specific resistance          
H 7 4 2.8 10.0 3.6
H, S 2 1 9.0 23.3 2.6
H, E 1 1   
H, Et 1 1   
H, R 16 9   
H, R, S 3 2 2.1 16.7 8.0
H, R, E 1 1   
H, R, E, Et 2 1   
H, R, S, E 1 1   
H, R, Z, S, Et 1 1   
Table 3- Risk factors for the development of drug-resistant tuberculosis 
in Cabo de Santo Agostinho.
                                 Tuberculosis*
                       resistant    not resistant  
no % no % Risk relative p
Gender  34
yes 20  21.3 74 78.7 1.13 [0.62-2.07] 0.82227
no 15  18.8 65  81.3
Sex female     
yes 11  20.8 42  79.2 1.05 [0.55-1.98] 0.94727
no 24  19.8 97  80.2
Alcohol consumption
yes 22  18.6 96  81.4 0.76[0.42-1.39] 0.49836
no 13  24.5 40  75.5
Employment     
yes 12  19.7 49  80.3 1.05 [0.53-2.11] 0.94345
no 14  18.7 61  81.3
Income  2
national minimum     
salaries     
yes 25  22.7 85  77.3 1.70 [0.82-3.54] 0.20160
no 8 13.3 52  86.7
Illiterate     
yes 11  27.5 29  72.5 1.51 [0.81-2.81] 0.28995
no 8 18.2 108  81.8
Previous treatment     
yes 15 50   50 3.60 [2.09-6.19] 0.00002
no 20 13.9 15  50.0
Abandonment   86  
yes 10  52.6 9 47.4 3.26 [1.87-5.70] 0.00057
no 25  16.1 130 83.9
*missing data was subtracted before statistical analysis. 
data relating to retired status was excluded from employment variable.
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(RR = 4.9; 95% CI = 2.48-9.77; p = 0.00004) and treatment 
abandonment (RR = 3.7; 95% CI = 1.82-7.56; p = 0.0033). 
Among the 232 notified TB cases, 185 underwent HIV testing: three 
samples were found to be positive and 13 were inconclusive, giving 
a frequency of TB-HIV coinfection of 1.6%. None of the MDR-TB
cases were positive for HIV infection.
DISCUSSION
In the present study, MDR-TB, defined as resistance to at least 
isoniazid and rifampicin was responsible for 14% of the overall 
number of TB cases and 69% of the drug-resistant TB cases in 
the City of Cabo de Santo Agostinho. The prevalence of MDR-TB
was as high as 8% among new TB cases and 40% among patients 
with previous treatment for the disease. 
There is still not enough data published on MDR-TB in Brazil. 
A retrospective study covering one decade (1990-1999) in Ceará, 
another city in northeastern Brazil, reported an acquired MDR-TB 
frequency of 0.6%2. In Rio de Janeiro, a Brazilian city with high 
demographic density and a poor situation regarding tuberculosis, 
the frequency of acquired MDR-TB in the year 1994 was 5.2%13.
More recently, a study in a district of São Paulo, Brazil’s largest 
city, reported a frequency of 16.7% for the year 2000-200221. Such 
differences in MDR-TB prevalence as observed in Brazil have also 
been reported in other countries. One example is Bangladesh, 
which has an overall MDR rate of 5.5% but considerably higher 
levels in the regions of Dhara (14.3%) and Matlab (27.3%)25. The 
resistance rate observed in Cabo is, on the other hand, similar 
to rates reported in some regions where drug resistance and 
MDR have been reported to be a major concern such as 54% in 
Lithuania4, 40.2% in Uzbekistan3 and 30.5% in Taiwan7.
The primary MDR level of 8% was also higher than the 0.1% 
observed during the national survey23 and was comparable with 
the reported 5.8% in Mozambique14, 6% in Colombia12, 9.3% 
in Lithuania4 and 13% in Uzbekistan3. It has been reported that 
countries with cure rates greater than 85% have primary MDR-
TB levels of less than 5% and that the prevalence of MDR-TB is 
ten times higher among previously treated patients than in new 
cases16. This reinforces the idea that primary MDR are related to 
failing TB control programs, while secondary MDR seems to be a 
consequence of lack of treatment compliance. In Cabo, the cure 
rate is currently still below 85%. Before the intervention of the TB 
Control Program in 2002, the rate of abandonment of treatment 
was as high as 15%. These epidemiological characteristics may 
have contributed towards the high levels of both types of resistance 
in the region, thereby leading to the present prevalence of primary 
MDR-TB of 8%.
One important finding was the ratio between acquired and 
primary resistance when considering resistance to one or more 
drugs: this ratio was 3.6 for monoresistance, 2.6 when there was 
resistant against any two drugs and 8.0 against three or more 
drugs. The greater this ratio was, the higher the acquired resistance 
was, which could be explained by the historical high frequency of 
treatment abandonment in Cabo, even though the incidence and 
prevalence rates were shown to be relatively stable (Table 1). 
A retrospective study on the prevalence of resistance to at 
least one drug was performed in Turkey, covering three decades 
starting in 1972. In this, an increase of 1.4% in the ration between 
acquired and primary MDR was observed for each decade. This 
was accompanied by decreases in the ratio between acquired and 
primary resistance to any drug over the three decades (6.5, 5.1 
and 4.6), thus suggesting that the increase in MDR prevalence 
was due to rises in primary resistance8.
Although the time frame of our study was too short for such 
an analysis, a lower ratio of acquired and primary MDR-TB (4.8) 
was observed in comparison with the ratio for resistance to three 
or more drugs (8.0). In the present study, the ratio between 
acquired and primary combined resistance to INH and RPM
was 3.2, 4.8 or 8.0, depending on whether the cases were only 
resistant to INH and RMP, were resistant to at least INH and RMP
or were associated with resistance to other drugs. This observation 
could be interpreted to mean that specific resistance to INH and 
RMP might be occurring as a consequence of lack of effective 
TB-control strategy in Cabo. This would lead to an increase in 
the primary resistance to specific drug combinations, thereby 
lowering the ratio in relation to that of MDR-TB.
We found a level of primary monoresistance against INH 
of 14% and absence of monoresistance to RMP. The observed 
pattern of resistance differed from the data presented in a 
recent review of 21 studies on the levels of primary resistance 
among Mycobacterium tuberculosis isolates in India, a country 
that accounts for 30% of TB cases worldwide. A high median 
prevalence of primary resistance to INH of 16.5% (3.2-32.9%) was 
observed, in comparison with the level of 2.85% (0-11.8%) for 
RMP and 1.5% (0-5.3%) for combined INH and RMP resistance17.
A population study in Rio de Janeiro, in 1994 showed a similar 
behavior of resistance frequency: 4.6% and 0.9% for primary 
monoresistance to INH and RMP respectively and 0.7% for the 
combined resistance13. This was because the mutation rate for 
genes involved in INH resistance was higher than that reported 
for rifampicin resistance. Double mutation is therefore a rare 
event: the development of combined resistance to INH and RMP
is unlikely to occur if the patient receives adequate care. 
Cases of acquired resistance are reported to be due to 
inappropriate or irregular drug supply or to patient behavior 
manifested by nonadherence to treatment, thereby favoring the 
selection of spontaneously mutated Mycobacterium tuberculosis
strains19. In the present study, the patients who had a history of 
previous treatment at the time of diagnosis had a five times greater 
risk of presenting MDR-TB. This association has also been found 
by other authors5 6 10 20. A history of abandonment of treatment was 
also found to lead to four times greater risk of having MDR-TB in 
Cabo. In addition to the frequency of abandonment of treatment in 
Cabo of 15% when the study began, we found a high frequency of 
alcohol consumption, which has been reported to be a risk factor 
for treatment abandonment1.
The frequency of HIV coinfection in TB patients in Cabo was 
1.6%. In Brazil, the rate of TB coinfection in patients with HIV/AIDS 
has been estimated to be 3-4% of cases9. All the patients with 
HIV infection reported here had TB caused by drug-susceptible 
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Mycobacterium. Development of drug-resistant tuberculosis 
was, however, associated with HIV in five of the seven European 
countries reporting this variable in a recent published systematic 
review5.
In conclusion, primary and secondary resistance to both INH 
and RMP was high in Cabo, thus suggesting that MDR strains are in 
circulation. This demonstrates the patchy nature of the degree of 
MDR and suggests that it may be very important to study regional 
variations. Culturing and resistance testing is recommended 
for all previously treated cases of TB, for cases without clinical 
improvement after two months of therapy and for new patients with 
close contacts that present MDR-TB. Therefore, the main challenge 
for TB control programs is to provide good laboratory support and 
to ensure that physicians are informed about the results from the 
laboratory tests. Decisions regarding adjustment of TB treatment 
schedules should be discussed in all cases with monoresistance 
to INH, including the addition of new drugs to the therapeutic 
schedule and using longer treatment periods. Application of 
molecular methods to genotype strains, with identification of 
mutations causing drug resistance among patients who do not 
respond well to treatment, could be an additional tool for avoiding 
delayed cure, transmission of MDR strains and mortality.
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